Cambridge-based cancer drug discovery firm Mosaic Therapeutics has closed a £22m ($28m) Series A funding round. The investment was raised by Syncona Investment Management and Cambridge Innovation Capital. Mosaic Therapeutics has also announced the appointment of former Novartis Oncology SVP Brian Gladsden as CEO. Gladsden, a 25-year biopharmaceuticals veteran, said: “I believe that Mosaic is … Continue reading Cancer drug discovery firm closes £22m Series A raise